Peptide Vaccine Targeting KRAS Mutations Promising for Pancreatic Ductal Adenocarcinoma

FRIDAY, July 17, 2026 (HealthDay News) -- A peptide vaccine targeting six common KRAS mutations (mKRAS-VAX) generates durable T-cell responses in individuals with hereditary pancreatic ductal adenocarcinoma (PDAC) predisposition, according to a study published online July 16 in Cancer Discovery.S. Daniel Haldar, M.D., from The University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a phase 1, first-in-human study evaluating mKRAS-VAX in 20 individuals with hereditary PDAC predisposition and a radiographic pancreatic abnormality to assess safety, immunogenicity, and T-cell persistence.The researchers found that grade 1 or 2 adverse events occurred. A significant mKRAS-specific T-cell response was elicited by vaccination in 18 of 20 participants. Vaccine-induced mKRAS-specific clonotypes persisted for up to two years on longitudinal T-cell receptor sequencing. No participants developed PDAC during a median follow-up of 16.5 months."This long-lasting response is particularly noteworthy when assessing for possible interception of cancer, which requires long-lasting immunity," co-senior author Neeha Zaidi, M.D., from the Johns Hopkins University School of Medicine in Baltimore, said in a statement. "In addition, the vaccine was safe and well tolerated, supporting its use in larger cancer interception studies."Several authors disclosed ties to the biopharmaceutical industry; several authors have filed patents related to the KRAS peptides and/or T-cell receptors.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

Peptide Vaccine Targeting KRAS Mutations Promising for Pancreatic Ductal Adenocarcinoma

Related Stories

FDA Expands Use of First Sickle Cell Disease Gene Therapy for Children as Young as 2 Years

ctDNA More Accurate Than MCPyV Antibody Test for Merkel Cell Carcinoma Recurrence

Pembrolizumab-Belzutifan Tied to Improved Disease-Free Survival in Renal Cell Carcinoma

ASCO: Daraxonrasib Effective for Metastatic Pancreatic Ductal Adenocarcinoma